890898 | DOTMA

1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)


Powder

Size SKU Packaging Price
25mg 890898P-25mg 890898P-25mg 1 x 25mg $297.50
200mg 890898P-200mg 890898P-200mg 2 x 100mg $604.00

Chloroform

Size SKU Packaging Price
25mg 890898C-25mg 890898C-25mg 1 x 25mg 10mg/mL 2.5mL $297.50
200mg 890898C-200mg 890898C-200mg 2 x 100mg 25mg/mL 4mL $604.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}

DOTMA

DOTMA

1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)

DOTMA is one of the two most widely used cationic lipids for gene transfection. DOTMA is an effective transfection agent in vitro and in vivo. DOTMA induces a positive charge on the surface of liposomes which promotes efficient interactions between the cell membrane and the liposome.

 Ren T, Song YK, Zhang G, Liu D. Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther. 2000 May;7(9):764-8. doi: 10.1038/sj.gt.3301153. PMID: 10822303.

 

Hygroscopic
No
Light Sensitive
Yes
Molecular Formula
C42H84ClNO2
Percent Composition
C 75.23%, H 12.63%, Cl 5.29%, N 2.09%, O 4.77
Purity
>99%
Stability
1 Year
Storage Temperature
-20°C
CAS Number
104872-42-6
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
670.575
Exact Mass
669.619

Li C, Han X. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. Pharm Res. 2020 May 31;37(6):109. doi: 10.1007/s11095-020-02838-4. PMID: 32476052.

PubMed ID: 32476052

Meng J, Tagalakis AD, Hart SL. Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells. Sci Rep. 2020 Jan 23;10(1):1046. doi: 10.1038/s41598-020-57854-6. PMID: 31974512; PMCID: PMC6978385.

PubMed ID: 31974512

Patel S, Ryals RC, Weller KK, Pennesi ME, Sahay G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J Control Release. 2019 Apr 12;303:91-100. doi: 10.1016/j.jconrel.2019.04.015. [Epub ahead of print]

PubMed ID: 30986436

Gallego I, Villate-Beitia I, Martínez-Navarrete G, Menéndez M, López-Méndez T, Soto-Sánchez C, Zárate J, Puras G, Fernández E, Pedraz JL. Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders. Nanomedicine. 2019 Feb 18;17:308-318. doi: 10.1016/j.nano.2018.12.018. [Epub ahead of print]

PubMed ID: 30790710

Jilek JL, Zhang QY, Tu MJ, Ho PY, Duan Z, Qiu JX, Yu AM. Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity. Mol Ther Nucleic Acids. 2019 Mar 1;14:498-508. doi: 10.1016/j.omtn.2019.01.007. Epub 2019 Jan 24.

PubMed ID: 30753993

Tagalakis AD, Madaan S, Larsen SD, Neubig RR, Khaw PT, Rodrigues I, Goyal S, Lim KS, Yu-Wai-Man C. In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis. J Nanobiotechnology. 2018 Nov 27;16(1):97. doi: 10.1186/s12951-018-0425-3.

PubMed ID: 30482196

Yang Y, Kannisto E, Yu G, Reid M, Patnaik S, Wu Y. An immuno-biochip selectively captures tumor-derived exosomes and detects exosomal RNA for cancer diagnosis. ACS Appl Mater Interfaces. 2018 Nov 19. doi: 10.1021/acsami.8b13971. [Epub ahead of print].

PubMed ID: 30451486

Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, Tam YYC, Cullis PR. Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano. 2018 Apr 6. doi: 10.1021/acsnano.8b01516.

PubMed ID: 29614232